We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00809874
Recruitment Status : Completed
First Posted : December 17, 2008
Last Update Posted : November 10, 2009
Information provided by:

Study Description
Brief Summary:

The purpose of this study is to determine the effects of dietary protein on blood lipids and gut hormones after a fat-rich meal.

Hypothesis: Certain dietary proteins reduce the amount of fat circulating in the blood stream following a fat rich meal. The effect is dependant of both the quality and the quantity of protein ingested.

Condition or disease Intervention/treatment
Postprandial Lipaemia Postprandial Incretins Postprandial Inflammation Dietary Supplement: Casein Dietary Supplement: Whey Isolate Dietary Supplement: Whey Hydrolysate Dietary Supplement: Alphalact-Albumin

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects
Study Start Date : February 2008
Primary Completion Date : December 2008
Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dietary Proteins
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Casein Dietary Supplement: Casein
Active Comparator: Whey Isolate Dietary Supplement: Whey Isolate
Active Comparator: Whey Hydrolysate Dietary Supplement: Whey Hydrolysate
Active Comparator: Alphalact-Albumin Dietary Supplement: Alphalact-Albumin

Outcome Measures

Primary Outcome Measures :
  1. Triglyceride [ Time Frame: 0h- 1h- 2h- 4h- 6h- 7h- 8h postprandial ]

Secondary Outcome Measures :
  1. Incretins [ Time Frame: 0h -1h -2h -4h -6h -7h -8h Postprandial ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI >30 kg/m2 & <45 kg/m2

Exclusion Criteria:

  • Diabetes
  • lipid lowering drugs
  • Liver-, Kidney- and/or Heart Disease
  • Serious Hypertension (160/110)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00809874

Department of Clinical Nutrion
Aarhus, Denmark, 8000
Sponsors and Collaborators
Aarhus University Hospital
The Danish Obesity Research Centre
Nordic Centre of Excellence
Arla Foods
Principal Investigator: K Hermansen, Professor, MD Department of Endocrinology and Metabolism, Aarhus University Hospital
More Information

Responsible Party: Kjeld Hermansen, Professor, Chief Physician, MD, Dr.Med.Sci, Department of Endocrinology And Metabolism, Aarhus University Hospital
ClinicalTrials.gov Identifier: NCT00809874     History of Changes
Other Study ID Numbers: CERN-PPL-JHJ
First Posted: December 17, 2008    Key Record Dates
Last Update Posted: November 10, 2009
Last Verified: November 2009

Keywords provided by Aarhus University Hospital:
Postprandial Period
Postprandial Lipaemia
Subclinical Inflammation

Additional relevant MeSH terms:
Pathologic Processes
Lipid Metabolism Disorders
Metabolic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action